- Oral presentation
- Open Access
O24 - Mite allergy prevention study
© Zolkipli et al; licensee BioMed Central Ltd. 2014
- Published: 28 February 2014
- Food Allergy
- Skin Prick Test
- House Dust
- House Dust Mite
- Cumulative Rate
Infants with family history of atopy are considered at high risk for developing allergic disease. Environmental exposures are modifiable risk factors with a potential for intervention to prevent allergy. Children who develop house dust mite (HDM) sensitisation by pre-school age are at higher risk of developing asthma. Prevention of HDM sensitisation in early childhood by immune modulation may consequently prevent development of asthma. We sought to achieve this by inducing tolerance to HDM through high dose allergen exposure.
We aim to provide preliminary evidence of efficacy and safety of sublingual immunotherapy with HDM in reducing the development of atopy among infants of high-risk families.
We conducted a randomised, double-blind, placebo-controlled trial over 2 sites: Southampton and the Isle of Wight. Infants at high risk (at least 2 first-degree relatives with atopy) were recruited at 5-6 months of age and remained on the intervention for 12 months. Exclusion criteria were skin prick test (SPT) positivity to screening food and aeroallergens, prematurity and concurrent major health problems. Participants underwent clinical and immunological assessments at baseline. The intervention was sublingual immunotherapy of either house dust mite extract or saline (ALK-Abello, Denmark). Assessment, including SPT was performed every 3 months to monitor development of allergic symptoms and SPT positivity (atopic sensitisation).
We recruited a total of 111 participants. At baseline 42% had objective evidence of eczema, 29% had parental report of wheeze and 20% had parental report of food allergy. To date, 66 infants have completed the study. Of these, 14 showed atopic sensitisation to at least 1 allergen (cumulative rate 21%). There have been no adverse reactions directly related to the interventional product.
We have demonstrated the safety of sublingual immunotherapy using HDM in high-risk infants with a cumulative rate of atopic sensitisation of 21% over 12 months.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.